|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study highlights the importance of PSD-95 during neurodevelopment in the mPFC and its potential link in the pathogenesis associated with schizophrenia and/or autism.
|
31263190 |
2019 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This result suggests that PSD95 may be involved in behavioral abnormalities of schizophrenia.
|
31112730 |
2019 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among the results, we found a significant reduction in synaptophysin in schizophrenia in the hippocampus (effect size: -0.65, p < 0.01), frontal (effect size: -0.36, p = 0.04), and cingulate cortices (effect size: -0.54, p = 0.02), but no significant changes for synaptophysin in occipital and temporal cortices, and no changes for SNAP-25, PSD-95, VAMP, and syntaxin in frontal cortex.
|
29511299 |
2019 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, we also found nine common DEGs between the mPFC and striatum of <i>Shank3</i> TG mice, among which we further characterized ASD- and SCZ-associated G protein-coupled receptor 85 (<i>Gpr85</i>), encoding an orphan <i>Gpr</i> interacting with PSD-95.
|
30233305 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Netrin-G ligand 2 (NGL-2)/LRRC4, implicated in autism spectrum disorders and schizophrenia, is a leucine-rich repeat-containing postsynaptic adhesion molecule that interacts intracellularly with the excitatory postsynaptic scaffolding protein PSD-95 and trans-synaptically with the presynaptic adhesion molecule netrin-G2.
|
29949768 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Understanding the role of PSD-95 in the neuropathologies of SCZ and autism will give an insight of the cellular and molecular attributes in the disorders, thus providing treatment options in patients affected.
|
29169997 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings describe a unique pathophysiology of specific PSD-95 isoform dysregulation in schizophrenia, chronic neuroleptic treatment, and a genetic lesion mouse model of drastically reduced N-methyl-d-aspartate receptor (NMDAR) complex expression.
|
28126896 |
2017 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have recently reported that protein levels of FRMPD4, a multiscaffolding protein that modulates both Homer1 and postsynaptic density protein 95 activity, is altered in the schizophrenia postmortem brain, in regions involved in cognition.
|
26555035 |
2016 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Resequencing and Association Analysis of Six PSD-95-Related Genes as Possible Susceptibility Genes for Schizophrenia and Autism Spectrum Disorders.
|
27271353 |
2016 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Changes in cortical N-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide.
|
26013316 |
2016 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although no allelic or genotypic variances of this gene were observed, the possibility that SNPs within DLG4 represent a positive schizophrenia risk gene cannot be excluded.
|
23921260 |
2013 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Although no allelic or genotypic variances of this gene were observed, the possibility that SNPs within DLG4 represent a positive schizophrenia risk gene cannot be excluded.
|
23921260 |
2013 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The DLG4 expression levels between postmortem brain samples from schizophrenia patients showed no significant changes from controls.
|
23936182 |
2013 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SCZD hiPSC neurons showed diminished neuronal connectivity in conjunction with decreased neurite number, PSD95-protein levels and glutamate receptor expression.
|
21490598 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Our data indicate that the expression of the DLG4 gene is subject to regulation by the polymorphic markers at the core promoter region, 5' and 3'UTR of the gene, and is associated with the susceptibility of schizophrenia.
|
21151988 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data indicate that the expression of the DLG4 gene is subject to regulation by the polymorphic markers at the core promoter region, 5' and 3'UTR of the gene, and is associated with the susceptibility of schizophrenia.
|
21151988 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We measured transcript levels of CDC42, CDC42EP3, CDC42EP4; their interacting proteins (septins [SEPT2, 3, 5, 6, 7, 8, and 11], anillin), and other spine-specific proteins (spinophilin, PSD-95, and synaptopodin) in the DLPFC from 31 subjects with schizophrenia and matched normal comparison subjects.
|
20385374 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins.
|
19455133 |
2009 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the same subjects, PSD95 was unchanged in all three illnesses, while reduced NF-L expression was found in schizophrenia, especially in large cells of layer V. SAP102 expression was reduced in bipolar disorder restricted to small cells of layer II and large cells of layer III in bipolar disorder.
|
18033238 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
In the same subjects, PSD95 was unchanged in all three illnesses, while reduced NF-L expression was found in schizophrenia, especially in large cells of layer V. SAP102 expression was reduced in bipolar disorder restricted to small cells of layer II and large cells of layer III in bipolar disorder.
|
18033238 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This postmortem study examined mRNA expression of ionotropic glutamate receptor (iGluR) subunits and PSD95 in 5 precisely defined and dissected thalamic subdivisions (medial and lateral sectors of the mediodorsal nucleus; and the ventral lateral posterior, ventral posterior, and centromedian nuclei) of persons with schizophrenia and matched controls using quantitative PCR with normalization to multiple endogenous controls.
|
18462708 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further genetic studies in schizophrenia with other PSD-95-like molecules that interact with the glutamate system are suggested.
|
17093888 |
2007 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we performed western blot analysis to determine whether protein levels of NMDA receptor subunits (NR1, NR2A, NR2B) and associated PSD proteins (NF-L, PSD95, SAP102) are altered in schizophrenia.
|
16762023 |
2006 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found significant changes in the expression of NF-L in DLPFC, and PSD-95 and PSD-93 in ACC; increased transcript expression was associated with decreased protein expression, suggesting abnormal translation and/or accelerated protein degradation of these molecules in schizophrenia.
|
16702973 |
2006 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression of SAP-102 in schizophrenia and SAP-102 and PSD-95 in mood disorders in subcortical structures receiving afferent glutamatergic innervation from frontal cortex suggests dysregulation of cortical-subcortical circuitry in these illnesses.
|
16023328 |
2005 |